Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis
| Autor: | Angela Gause, Peter Lamprecht, C Lerin-Lozano, A C Arlt, Stefan O. Peters, Jan Voswinkel, R H Dennin, Wolfgang L. Gross, H Merz, Werner Solbach, O Gutzeit |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Vasculitis
Concise Report Cyclophosphamide Immunology Alpha interferon Antineoplastic Agents Interferon alpha-2 Antiviral Agents General Biochemistry Genetics and Molecular Biology Antibodies Monoclonal Murine-Derived chemistry.chemical_compound Rheumatology immune system diseases Pegylated interferon hemic and lymphatic diseases Drug Resistance Viral Ribavirin Humans Immunology and Allergy Medicine CD20 biology business.industry Lymphoma Non-Hodgkin Remission Induction Antibodies Monoclonal Interferon-alpha virus diseases Hepatitis C Chronic Middle Aged medicine.disease Cryoglobulinemia Recombinant Proteins digestive system diseases chemistry Drug Resistance Neoplasm biology.protein Female Rituximab business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 62:1230-1233 |
| ISSN: | 0003-4967 |
| Popis: | To report the successful induction of remission with the monoclonal anti-CD20 antibody rituximab in a patient with hepatitis C virus (HCV) associated cryoglobulinaemic vasculitis and a non-Hodgkin's lymphoma (NHL) resistant to previously advocated conventional treatments.The patient was a 45 year old woman with HCV associated cryoglobulinaemic vasculitis, with purpura, arthralgia, constitutional symptoms, and a polyneuropathy. A malignant NHL was found as underlying lymphoproliferative disease. At this stage the disease was refractory to interferon alpha2b and ribavirin and to subsequent immunosuppressive treatment with cyclophosphamide. Six rituximab infusions targeting the CD20 antigen on cells of the B cell lineage induced remission of the vasculitis. Bone marrow biopsy disclosed absence of the NHL. Remission has subsequently been maintained and HCV eliminated with the new pegylated interferon alpha2b and ribavirin for nearly one year.Transition of the underlying "benign" lymphoproliferative disease to a malignant lymphoma may result in difficult to treat HCV associated cryoglobulinaemic vasculitis. Rituximab offers a new possibility for inducing remission in refractory HCV associated cryoglobulinaemic vasculitis and the lymphoproliferative disorder. After remission, HCV may subsequently be eliminated with pegylated interferon alpha2b and ribavirin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|